The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
Open accessAbstract
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst 1,2,3) and sst 5. Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was a phase II, open-label, multicenter study of pasireotide in patients with advanced NET whose symptoms of carcinoid syndrome (diarrhea/flushing) were inadequately controlled by octreotide LAR. Patients received s.c. pasireotide 150 μg twice daily (bid), escalated to a maximum dose of 1200 μg bid until a clinical response was achieved. Forty-four patients were evaluated for efficacy and 45 for tolerability. Pasireotide 600–900 μg s.c. bid effectively controlled the symptoms of diarrhea and flushing in 27% of patients. Evaluation of tumor response in 23 patients showed 13 with stable disease and ten with progressive disease at study end. The most common drug-related adverse events were nausea (27%), abdominal pain (20%), weight loss (20%), and hyperglycemia (16%) and most were of mild or moderate severity. Pasireotide 600–900 μg s.c. bid was effective and generally well tolerated in controlling the symptoms of carcinoid syndrome in 27% of patients with advanced NET refractory or resistant to octreotide LAR therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G., & Weckbecker, G. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460707 · Cited by 692
Cited by
Pavel, M., O''Toole, D., Costa, F., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E., Knigge, U., Salazar, R., Pape, U.-F., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,041
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Somatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas-Salas, J., & Álvarez-Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 264
Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors
Davar, J., Connolly, H. M., Caplin, M. E., Pavel, M., Zacks, J., Bhattacharyya, S., Cuthbertson, D. J., Dobson, R., Grozinsky-Glasberg, S., Steeds, R. P., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.030 · Cited by 261
Cives, M., Kunz, P. L., Morse, B., Coppola, D., Schell, M. J., Campos, T., Nguyen, P. T., Nandoskar, P., Khandelwal, V, & Strosberg, J. R. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-14-0360 · Cited by 96
Metadata
- Authors
- Kvols, L. K., Oberg, K. E., O'Dorisio, T. M., Mohideen, P., de Herder, W. W., Arnold, R., Hu, K., Zhang, Y., Hughes, G., Anthony, L., & Wiedenmann, B.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2012-07-17
- Volume
- 19
- Issue
- 5
- Pages
- 657-666
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2135503195
- Cited by
- 199
- References
- 1
- FWCI
- 16.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. https://app.cochat.ai/papers/10.1530/erc-11-0367
- The paper
- Kvols, L. K., Oberg, K. E., O'Dorisio, T. M., Mohideen, P., de Herder, W. W., Arnold, R., Hu, K., Zhang, Y., Hughes, G., Anthony, L., & Wiedenmann, B. (2012). Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocrine-Related Cancer. https://doi.org/10.1530/erc-11-0367
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.